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Abstract
Chronic kidney disease (CKD) in childhood is associated with neurocognitive deficits. Affected 
children show worse performance on tests of intelligence than their unaffected siblings and skew 
toward the lower end of the normal range. Here we further assessed this association in 340 
pediatric patients (ages 6 to 21) with mild-moderate CKD in The Chronic Kidney Disease in 
Childhood cohort from 48 pediatric centers in North America. Participants underwent a battery of 
age-appropriate tests including Conner’s Continuous Performance Test-II (CPT-II), Delis- Kaplan 
Executive Function System Tower task, and the Digit Span Backwards task from the age-
appropriate Wechsler Intelligence Scale. Test performance was compared across the range of 
estimated GFR and duration of CKD with relevant covariates including maternal education, 
household income, IQ, blood pressure and preterm birth. Among the 340 patients, 35% had poor 
performance (below the mean by1.5 or more standard deviations) on at least one test of executive 
function. By univariate nonparametric comparison and multiple logistic regression, longer 
duration of CKD was associated with increased odds ratio for poor performance on the CPT-II 
Errors of Commission, a test of attention regulation and inhibitory control. Thus, in a population 
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with mild to moderate CKD, the duration of disease rather than estimated GFR was associated 
with impaired attention regulation and inhibitory control.
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Introduction
Chronic kidney disease (CKD) in adults is associated with cognitive impairment which may 
be related to kidney function as measured by glomerular filtration rate (GFR) and the 
presence of albuminuria [1–5]. Possible mechanisms for cognitive impairment include 
accelerated cerebrovascular disease with ischemia, subclinical stroke and subcortical 
atrophy [6–8] mimicking the pattern of age-related cognitive decline. However, the effects 
of CKD on cognitive function in childhood are clearly different. Childhood and adolescence 
are periods of brain growth and the development of neural pathways responsible for 
comprehension, memory, planning, problem solving, abstract reasoning and attentional 
control; decreased GFR or other effects of chronic illness may adversely affect these normal 
developmental processes [9,10]. Measuring these effects in children needs to be approached 
differently than is done in adults.
The early literature on childhood CKD shows its association with encephalopathy and 
developmental delay, especially of gross motor skills and language acquisition [11–14]. 
Case series show that when the uremic milieu coincides with critical periods of brain 
development, it can cause non-specific EEG abnormalities [15,16] as well as structural 
changes including atrophy and infarcts [17–19]. Such severe deficits have become less 
common with the elimination of oral and dialytic aluminum intake and the avoidance of 
uncontrolled uremia [20,21]. Nonetheless, there remains evidence for subtle neurocognitive 
deficits in children with advanced chronic kidney disease. Children with CKD perform less 
well on standardized tests of intelligence and academic achievement than their unaffected 
siblings [22]. Prospective studies have demonstrated that cognitive deficits can improve 
after kidney transplantation [23,24]. Lawry et al showed better neurocognitive function and 
school performance among transplant patients when compared to chronic dialysis 
patients[25].
Neurocognitive impairment has been described in other chronic diseases of childhood, 
including systemic lupus erythematosus (SLE), juvenile rheumatoid arthritis (JRA), 
inflammatory bowel disease (IBD) and cancer chemotherapy. Estimates of neurocognitive 
impairment in childhood SLE vary depending upon the test battery used, the cohort and 
controls studied and the categorization of cognitive impairment. Two studies demonstrated 
incidences of impairment ranging from 59–71% of small study groups [26, 27]. In a 
prospective study with age- and ethnicity-matched controls in addition to standardized 
norms, SLE subjects and controls performed similarly [28]. Subjects with renal disease were 
over-represented in the group with neurocognitive impairment, but this did not reach 
statistical significance. A study of 31 subjects with systemic JRA showed no difference in 
Mendley et al. Page 2













WISC-R and WAIS-R, information processing speed, memory and verbal learning when 
compared with an age and socio-economically matched control group [29]. Adolescents 
with IBD made more errors in tests of verbal learning than a comparable group with JRA, 
yet performed similarly on other tests of memory, intelligence and executive function[30].
The neurotoxic effects of chemotherapy for childhood cancer have been extensively studied. 
Risk factors for neurocognitive sequelae after acute lymphoblastic leukemia (ALL) include 
younger age at diagnosis, female sex and intensity of treatment, particularly systemic high 
dose methotrexate [Buizer31]. Cranial radiation was used in earlier studies of ALL to 
prevent central nervous system relapse but effects on IQ and academic performance have 
driven protocols toward chemotherapy alone.
Subjects with advanced renal failure have more often been reported, but the effects of early 
chronic kidney disease on neurocognitive function remain incompletely elucidated. 
Published results from the NIH-sponsored Chronic Kidney Disease in Children Study 
(CKiD) have shown that IQ and academic achievement in children with mild-to-moderate 
CKD cluster at the lower end of the normal range and the distribution is skewed 
downward[32]. Whether the severity of CKD or the duration of exposure to low GFR during 
brain development is of greater importance is not fully understood.
Executive function (EF) is the central cognitive process that controls problem solving to 
permit goal-directed behavior. Various conceptual and empirical models of EF have been 
proposed, but most include: inhibition of prepotent responses, shifting mental sets, 
monitoring and regulating performance, planning and problem solving, and working 
memory capacity. Control of attention is included in a construct linking EF and working 
memory capacity. [33–39] Additionally, executive processes are considered critical to the 
integrity of many learning and social-behavioral functions [35] and each of these functions 
has a developmental basis that will exert effects on learning and behavior at different times, 
with a sequential unfolding of executive functions from infancy into early adulthood [40, 
41]. Consequently, brain injury or toxic exposure during this period of developmental 
ascendancy would be expected to have an effect on the integrity of EF [42].
Several assessments of EF were incorporated into the CKiD study to determine if EF is 
particularly sensitive to perturbation in a uremic milieu [43] and if abnormalities of 
performance could be detected early in the course of CKD. The objective of the current 
study was to estimate the prevalence of EF deficits in children with mild-to-moderate CKD 




Subjects were enrolled in the CKiD study at ages 1–16 and followed prospectively. The 
neurocognitive testing in this cross-sectional analysis was administered to 340 subjects age 
6–21 years. Characteristics of this study sample are shown in Table 1. With a median age of 
13, the group was 61% male and 83% Caucasian, and the median parent-reported duration 
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of CKD diagnosis was 10 years. One quarter of the study group had blood pressure 
measured >90th percentile (for age, height, and gender) on the day of cognitive testing. 
Because of the age of the subjects, there were no diabetics; SLE was present in only 2% and 
depression in 7%. Median estimated GFR (eGFR) for the group was 43 ml/min/1.73m2 
(interquartile range, 31–53). As reported for the entire cohort [32], IQ clustered at the low 
range of normal and 22% of the study sample had IQ scores <85; this was incorporated into 
statistical models. All subjects attended school and the median grade level at the time of 
testing was 6th (IQR 3, 9). Forty percent of subjects were below expected grade level. The 
median number of days absent from school for medical reasons was 4 (IQR 2, 8) and 11% of 
the study group was absent 18 or more days in the preceding school year.
In anticipation of potential confounders, such as fatigue secondary to order effects, the tests 
were separated into two blocks, and the blocks were administered in a counterbalanced 
format across subjects. Additionally, we obtained validity ratings by the psychologists to 
determine the quality of the test administration and test data. All tests had excellent 
reliability; 93% of CPT, 96% of Digit Span Backward and 94% of D-KEFS had the highest 
validity rating of 1.0. Given the critical impact of fatigue on attention regulation and 
associated executive functions, we also assessed fatigue using the Peds QL [44]; 17% of the 
group indicated low energy often or almost always on either the parent or child report on the 
day of EF testing.
Thirty-five percent of the study group (119 subjects; 95% confidence interval [CI]: 30–41%) 
performed poorly (≥1.5 SD below mean) on at least one test of EF. Of these subjects, 79 
performed poorly on only one test, 30 on two tests and 10 performed poorly on 3 or more 
tests. Some subjects were unable to complete the tasks or had missing values on at least one 
test in the battery.
Factors Associated with Poor EF Performance
Table 2 displays the median and IQR of duration of CKD and eGFR for each poor-
performance group and its complement. By nonparametric comparison, longer duration of 
disease was associated with poor performance on the Connor’s Continuous Performance test 
(CPT-II) Errors of Commission (p=0.004). No other comparisons approached statistical 
significance.
Multiple logistic regression models used to examine the association of duration of CKD and 
impairment of GFR on the likelihood of deficient performance on EF tests are shown in 
Table 3. After controlling for race, maternal education, household income, IQ, blood 
pressure, premature birth and proteinuria, which were defined as relevant covariates in 
previous publications from this cohort [32, 45], the level of eGFR was not associated with 
increased odds of poor performance on any of the EF tasks. By contrast, longer duration of 
CKD was associated with increased odds of poor performance on the CPT-II Errors of 
Commission, with an odds ratio of 1.16 (p = 0.013; 95% CI: 1.03–1.31). This estimate can 
be interpreted as a doubling of the odds of poor performance for every 4.6 years of CKD 
exposure. Additional logistic regression analysis showed elevated BP (>90th percentile for 
age, height and gender) was associated with a greater degree of variability in CPT 
performance (less consistent performance of the task, p<0.01), while higher household 
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income was protective, associated with a lesser degree of CPT variability (p<0.05). 
However, poor performance in planning and problem solving on the D-KEFS Tower Task 
was not predicted either by severity or duration of CKD. Working memory as assessed by 
Digit Span Backward was not affected by either the duration of known CKD or the level of 
GFR; however, the highest level of maternal education (college degree or higher) was 
protective against poor performance in working memory (OR 0.20, p=0.049; 95% CI 0.04–
0.99).
Multiple linear regression with correction for multiple testing showed no significant 
association with eGFR, duration of CKD, elevated blood pressure, proteinuria, or preterm 
birth on performance of any of the EF tasks as continuous variables across the full range of 
performance (data not shown). As expected, low IQ (full scale IQ < 85) had a significant 
deleterious effect on performance and subjects with IQ<85 were over-represented in the 
poor performing group for each task. For that reason our logistic regression model 
incorporated IQ as a relevant covariate (see below). Higher maternal education (college 
degree or more) was associated with improved performance only on Digit Span Backward 
(estimate of effect size 1.07). The EF composite score did not improve the predictive value 
of any variable on the likelihood of deficient performance.
Discussion
Our data show that longer CKD duration is associated with an increased likelihood of poor 
performance in inhibitory control and visual vigilance as measured by errors of commission 
on the Connors’ CPT-II, which suggests abnormal attention regulation. This observation was 
supported by both univariate analysis and multiple logistic regression. However, we did not 
demonstrate an effect of GFR on CPT-II performance. Attention is only one component of 
executive function; the risk of poor performance on tasks which tap other aspects of EF, 
including the Delis-Kaplan Executive Function System Tower Task (DKEFS) and the 
Wechsler Intelligence Scale for Children Fourth Edition (WISC) or Wechsler Adult 
Intelligence Scale Fourth Edition (WAIS) Digit Span Backwards, was not associated with 
either duration of CKD or GFR.
Our current finding is concordant with the work of Fennell [46], who reported poorer 
attention regulation in children with CKD when compared to age-matched controls. Another 
prospective study of children with ESRD showed that inhibitory control, as measured by 
CPT-II, appeared to be sensitive to uremia [23]. When these subjects were restudied (within-
subject comparison) after kidney transplant with near-normal GFR, they demonstrated 
improved performance on the CPT-II, with fewer errors of commission [23]. Those 
publications, along with the findings from the present study, support an effect of CKD on 
attention and inhibitory control, and also support the use of the CPT-II as a relevant tool in 
this setting and the CKD population in general.
Our results suggest that we have identified a specific area of poor neurocognitive 
performance in this population and may provide a mechanistic insight into the effect of 
CKD. The CPT-II specifically assesses attention regulation and requires sustained focus on a 
repeated task and the ability to consistently suppress incorrect responses. If a subject allows 
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attention to waver, he will miss correct responses (errors of omission); if he fails to suppress 
a response to an incorrect stimulus (i.e. lack of inhibitory control) he will exhibit errors of 
commission. If a subject’s reaction time performance varies through a test session as he tires 
or fails to sustain attention, he will manifest increased response variability. In this study, our 
subjects demonstrated poor performance in both aspects: longer duration of CKD was 
associated with errors of commission and increased variability of performance was 
associated with elevated blood pressure.
It is notable that our cross-sectional findings show duration of disease to be more relevant 
than the level of GFR, and suggest that CKD may have a subtle but persistent effect on 
neurodevelopmental processes. Further complicating our understanding of this effect are the 
multiple comorbid events and their sequelae which may occur in the course of childhood 
chronic disease. The literature documents developmental impairment in infants and toddlers 
with CKD and those requiring dialysis in infancy [11–13], and we may be able to detect a 
more subtle but still relevant effect in children who have had a milder but longer exposure to 
renal disease. Some children with congenital urologic abnormality have a long duration of 
known disease and one could postulate an early impact on neurodevelopment at a critical 
early period or that their early diagnosis may skew the analysis. However the comparison of 
non-glomerular and glomerular renal disease grouping has not yielded important differences 
in neurocognitive function.
Low IQ was clearly associated with poor EF performance on all tasks and we are left with 
the theoretical question as to whether low IQ leads to poor EF or whether poor EF leads to 
low IQ. It is equally likely that causes of CKD and numerous comorbid events affect both 
EF and IQ and these may not be separable in a heterogeneous population like ours. We 
controlled for low IQ in the logistic regression model, but must consider if that was 
sufficient. Removing low IQ subjects entirely from the analysis limited the statistical power 
too much to allow meaningful conclusions. We also considered the option of not controlling 
for IQ, given that it tends to be a summary variable for a number of cognitive functions[47], 
but elected to control for this variable given the number of cases with low IQ in the sample. 
At a minimum, these findings reflect a conservative approach to our data analyses and 
increase confidence in the associations uncovered.
The CKiD study was prospectively designed to provide a systematic assessment of 
numerous aspects of childhood CKD. We have focused our analysis on attention and 
executive functions in the study population which spans a wide spectrum of age and GFR. 
Unlike some studies in adult cohorts which, by necessity, used widely available but more 
rudimentary tools for assessing cognitive abilities, experienced child psychologists designed 
and performed an age appropriate battery of EF tests.
Pediatric studies cited previously [14] focused on children with advanced CKD, but the 
goals of the CKiD study are to follow subjects with mild to moderate renal dysfunction to 
find the earliest effects of the disease and permit longitudinal reassessments. As such, many 
disturbances of cognitive and intellectual function described in children with advanced CKD 
are expected to be more subtle or not yet apparent in our subjects who are still early in their 
disease course. Yet, it is notable that more than a third of our subjects performed poorly on 
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at least one test of EF. While we did not demonstrate a correlation of EF abilities with level 
of GFR, this observation is consistent with some well-controlled adult studies [2,5]. There 
are significant lifelong implications of diminished EF that may limit full rehabilitation from 
childhood CKD, including medication adherence, performance at higher levels of schooling 
and employment.
The current study has several limitations. The range of GFRs in the study population may 
not have been wide enough to detect the full effects on EF. Subjects with longer duration of 
disease may have had other coexisting conditions which our analysis did not reveal, but 
which may have impacted cognition or cognitive development. That the effect of duration of 
CKD on CPT errors of commission was demonstrated by logistic regression but not by 
linear regression may reflect the variable disease course or the milder degree of renal 
impairment in the study population; however, we must consider that the effect may be quite 
weak. Further, only one component score of the CPT test reached significance and again we 
must consider whether the effect is real or spurious. In fact, poor performance on the CPT 
may be the result of lack of engagement in the task rather than a true deficit of attention 
regulation, although it is important to note that we counterbalanced our tasks and ratings of 
the quality of the administrations/data were excellent. The cross-sectional study design 
limits the ability to make inferences regarding the cause of the decreased EF found in some 
subjects and the effect sizes were relatively small. Our interpretation of the impact of uremia 
on EF is limited by the early stage of CKD, with only modestly decreased GFR in many 
subjects. It will be important to track this relationship over time; the CKiD study will re-
evaluate each subject’s performance longitudinally in relation to change in GFR.
The CKiD study is an ambitious attempt to capture the full impact of chronic kidney disease 
in an evolving cohort of children who are experiencing progression of renal dysfunction, 
ongoing somatic growth, cardiovascular changes, and coincident cognitive and emotional 
development. Separating the overlapping effects of all these variables remains a challenge 
well worth pursuing. We provide early results with the clear intention to continue 
investigations.
Materials/Methods
CKiD is a prospective cohort study of children ages 1–16 years at recruitment with chronic 
kidney disease (estimated GFR 30–90 ml/min/1.73m2) which is conducted at 48 pediatric 
nephrology centers in North America. Details of the study design and methods have been 
published previously [48]. In this analysis we have looked at all subjects aged 6 and older 
and results are limited to ages for which there are normative data. Children with intellectual 
disabilities and those with genetic syndromes with central nervous system manifestations 
were excluded by study design. The protocol was approved by the Institutional Review 
Boards of all centers.
Kidney Function
The CKiD study includes a reliable method of GFR measurement by iohexol clearance at 
defined study timepoints [49]. However we separated neurocognitive testing dates from 
clearance studies to avoid the distraction of iohexol infusion and phlebotomy. Previous 
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analysis of the iohexol clearance data has allowed generation of a validated, accurate 
method to estimate GFR (eGFR) using serum creatinine, cystatin C and blood urea nitrogen 
measurements [49, 50] and this was used to provide a contemporaneous eGFR at the time of 
neurocognitive assessment.
Assessment of Attention and Executive Function
The study protocol includes a battery of age-appropriate tests of EF performed by child 
psychologists at defined intervals (6 months after study entry, 1.5 years later and then every 
2 years). This analysis contains data from the first visit at which each subject had the 
complete EF battery done, so some subjects were more than 16 years of age by the time of 
testing. EF measures included the Conner’s Continuous Performance Test-II (CPT-II) which 
is a computer-based task that requires the subject to touch the mouse or space bar in 
response to visual stimuli (i.e., letters on computer screen) that are presented at the rate of 
about one per second over approximately a 14 minute testing period. The CPT-II provides 
information about the child’s omission and commission error rates, reaction time and 
response variability which represent an assessment of sustained attention and inhibitory 
control. The CPT-II measures are scaled to a mean = 50, SD = 10; higher scores indicate 
worse performance.
Included in the battery was the Delis-Kaplan Executive Function System Tower Task 
(DKEFS) in which subjects are asked to move a set of disks from one peg to another; only 
one disk can be moved at a time and a larger disk cannot be placed over a smaller disk. The 
task becomes more complicated as the number of disks increases and it draws upon skills of 
planning, reasoning, problem solving, and inhibitory control. Age-based norms for the Total 
Achievement Score (representing time required to complete the task correctly) are available 
for subjects age 8 years and older and only that age group is included in analysis. The 
DKEFS scores are scaled to a mean = 10, SD = 3; lower scores indicate worse performance.
Also included was an assessment of working memory using the Wechsler Intelligence Scale 
for Children Fourth Edition (WISC) or Wechsler Adult Intelligence Scale Fourth Edition 
(WAIS, for those subjects over age 16 at testing) Digit Span Backwards tasks, in which 
subjects are asked to repeat a list of verbally-presented numbers in reverse order. Age-based 
standardized norms for Digit Span Backward have a mean = 10, SD = 3 and lower scores 
indicate worse performance. In addition to the EF measures, we determine the estimated 
level of IQ for each subject using Full-4 from the Wechsler Abbreviated Scale of 
Intelligence.
Statistical Analysis
Performance on tests of executive function was compared across the range of GFR and CKD 
duration. Duration of CKD was determined by parent report of the child’s medical history 
and onset of disease at the first study visit and then corroborated with nephrologist’s records.
To address the primary research question, we identified subjects with poor performance on a 
test of EF, which was defined as a score ≥ 1.5 SD below the normal population mean on any 
of the five EF measures. On DKEFS and Digit Span Backward, poor performance 
corresponds to a scaled score ≤ 5.5; on CPT measures, poor performance corresponds to a T 
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score of ≥65. We stratified our sample by performance on each EF measure and examined 
the distributions of the primary exposures, duration of CKD and eGFR, testing for 
differences with Wilcoxon rank-sum tests. We used logistic regression to predict the 
likelihood of executive dysfunction by level of GFR or duration of CKD, adjusting for a 
targeted group of covariates or potential confounders including age, race, maternal 
education, household income, IQ, blood pressure, premature birth, and proteinuria. These 
covariates were selected from a wide range of potentially relevant patient characteristics 
based upon previously published neurocognitive findings from the CKiD study [32, 45]. To 
clarify the impact of renal disease on neurocognitive function, eGFR and duration of CKD 
were examined in separate models. We also explored adjusted linear regression models to 
assess potential effects on the continuous EF scales across the full range of performance.
We considered whether a global assessment might be a useful tool to identify relevant 
exposures affecting EF in this population. To test this, we created a composite score of the 
five EF measures by rescaling the scores to have the same mean and directionality and 
accounting for within- and between-measure variance, allowing an overall score of “poor” 
and “not poor”.
Acknowledgments
Data in this manuscript were collected by the Chronic Kidney Disease in Children prospective cohort study (CKiD) 
with clinical coordinating centers (Principal Investigators) at Children’s Mercy Hospital and the University of 
Missouri – Kansas City (Bradley Warady, MD) and Children’s Hospital of Philadelphia (Susan Furth, MD, Ph.D.), 
Central Biochemistry Laboratory (George Schwartz, MD) at the University of Rochester Medical Center, and data 
coordinating center (Alvaro Munoz, Ph.D) at the Johns Hopkins Bloomberg School of Public Health. CKiD is 
funded by the National Institute of Diabetes and Digestive and Kidney Diseases, with additional funding from the 
National Institute of Child Health and Human Development, and the National Heart, Lung, and Blood Institute 
(U01-DK-66143, U01-DK-66174, U01DK-082194, U01-DK-66116). The CKID website is located at http://
www.statepi.jhsph.edu/ckid.
References
1. Hailpern SM, Melamed MM, Cohen HW, et al. Moderate chronic kidney disease and cognitive 
function in adults 20 to 59 Years of Age: Third National Health and Nutrition Examination Survey 
(NHANES III). J Am Soc Nephrol. 2007; 18:2205–2213. [PubMed: 17554148] 
2. Tamura MK, Wadley V, Yaffe K, et al. Kidney function and cognitive impairment in US adults: The 
Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Am J Kidney Dis. 
2008; 52:227–234. [PubMed: 18585836] 
3. Tamura MK, Dawei X, Yaffe K, et al. Vascular risk factors and cognitive impairment in chronic 
kidney disease: The Chronic Renal Insufficiency Cohort (CRIC) Study. Clin J Am Soc Nephrol. 
2011; 6:248–256. [PubMed: 20930087] 
4. Tamura MK, Muntner P, Wadley V, et al. Albuminuria, kidney function, and the incidence of 
cognitive impairment among adults in the United States. Am J Kidney Dis. 2011; 58(5):756–763. 
[PubMed: 21816528] 
5. Joosten H, Izaks GJ, Slaets JPJ, et al. Association of cognitive function with albuminuria and eGFR 
in the general population. Clin J Am Soc Nephrol. 2011; 6:1400–1409. [PubMed: 21566108] 
6. Ikram MA, Vernooij MW, Hofman A, et al. Kidney function is related to cerebral small vessel 
disease. Stroke. 2008; 39:55–61. [PubMed: 18048865] 
7. Seliger SL, Longstreth WT Jr, Katz R, et al. Cystatin C and subclinical brain infarction. J Am Soc 
Nephrol. 2005; 16:3721–3727. [PubMed: 16236809] 
8. Kobayashi S, Ikeda T, Moriya H, et al. Asymptomatic cerebral lacunae in patients with chronic 
kidney disease. Am J Kidney Dis. 2004; 44:35–41. [PubMed: 15211435] 
Mendley et al. Page 9













9. Gerson AC, Butler R, Moxey-Mims M, et al. Neurocognitive outcomes in children with chronic 
kidney disease: current findings and contemporary endeavors. Ment Retard Dev Disabil Res. 2006; 
12(3):208–215.
10. Gipson DS, Duquette PJ, Icard PF, et al. The central nervous system in childhood chronic kidney 
disease. Pediatr Nephrol. 2007; 22(10):1703–10. [PubMed: 17072652] 
11. Rotundo A, Nevins TE, Lipton M, et al. Progressive encephalopathy in children with chronic renal 
insufficiency in infancy. Kidney Int. 1982; 21(3):486–91. [PubMed: 7087284] 
12. McGraw ME, Haka-Ikse K. Neurologic-developmental sequelae of chronic renalfailure in infancy. 
J Pediatr. 1985; 106(4):579–83. [PubMed: 3884761] 
13. Polinsky MS, Kaiser BA, Stover JB. Neurologic development of children with severe chronic renal 
failure from infancy. Pediatr Nephrol. 1987; 1:157–165. [PubMed: 3153274] 
14. Fennell RS, Fennell EB, Carter RL, et al. A longitudinal study of the cognitive function of children 
with renal failure. Pediatr Nephrol. 1990; 4:11–15. [PubMed: 2206873] 
15. Elzouki A, Carroll J, Butinar DI, et al. Improved neurological outcome in children with chronic 
renal disease from infancy. Pediatr Nephrol. 1994; 8(2):205–10. [PubMed: 8018500] 
16. Qvist E, Pihko H, Fagerudd P, et al. Neurodevelopmental outcome in high-risk patients after renal 
transplantation in early childhood. Pediatr Transplant. 2002; 6:53–62. [PubMed: 11906644] 
17. Schnaper HW, Cole BR, Hodges FJ, et al. Cerebral cortical atrophy in pediatric patients with end-
stage renal disease. Am J Kidney Dis. 1983; 2:645–650. [PubMed: 6601908] 
18. Steinberg A, Efrat R, Pomeranz A, et al. Computerized tomography of the brain in children with 
chronic renal failure. Int J Pediatr Nephrol. 1985; 6:121–126. [PubMed: 4030222] 
19. Valanne L, Qvist E, Jalanko H, et al. Neuroradiologic findings in children with renal 
transplantation under 5 years of age. Pediatr Transplant. 2004; 8:44–51. [PubMed: 15009840] 
20. Warady BA, Belden B, Kohaut E. Neurodevelopmental outcome of children initiating peritoneal 
dialysis in early infancy. Pediatr Nephrol. 1999; 13:759–65. [PubMed: 10603115] 
21. Warady BA. Neurodevelopment of infants with end-stage renal disease: is it improving? Pediatr 
Transplant. 2002 Feb.6:5–7. [PubMed: 11906634] 
22. Brouhard BH, Donaldson LA, Lawry KW, et al. Cognitive functioning in children on dialysis and 
post-transplantation. Pediatr Transplant. 2000; 4:261–7. [PubMed: 11079264] 
23. Mendley SR, Zelko F. Improvement in specific aspects of neurocognitive performance in children 
after renal transplantation. Kidney Int. 1999; 56:318–323. [PubMed: 10411708] 
24. Icard P, Hooper SR, Gipson DS, et al. Cognitive improvement in children with CKD after 
transplant. Pediatr Transplant. 2010; 14:887–90. [PubMed: 20667033] 
25. Lawry KW, Brouhard BH, Cunningham RJ. Cognitive functioning and school performance in 
children with renal failure. Pediatr Nephro. 1994; 8:326–9.
26. Brunner HI, Ruth NM, German A, et al. Initial validation of the Pediatric Automated 
Neuropsychological Assessment Metrics for childhood-onset systemic lupus erythematosus. 
Arthritis Rheum. 2007 Oct 15; 57(7):1174–82. [PubMed: 17907235] 
27. Muscal E, Bloom DR, Hunter JV, Myones BL. Neurocognitive deficits and neuroimaging 
abnormalities are prevalent in children with lupus: clinical and research experiences at a US 
pediatric institution. Lupus. 2010 Mar; 19(3):268–79. [PubMed: 20026519] 
28. Williams TS, Aranow C, Ross GS, et al. Neurocognitive impairment in childhood-onset systemic 
lupus erythematosus: measurement issues in diagnosis. Arthritis Care Res. 2011 Aug; 63(8):1178–
87.
29. Feldmann R, Weglage J, Roth J, et al. Systemic juvenile rheumatoid arthritis: cognitive function 
and social adjustment. Ann Neurol. 2005 Oct; 58(4):605–9. [PubMed: 16178013] 
30. Castaneda AE, Tuulio-Henriksson A, Aronen ET, et al. Cognitive functioning and depressive 
symptoms in adolescents with inflammatory bowel disease. World J Gastroenterol. 2013 Mar 14; 
19(10):1611–7. [PubMed: 23538788] 
31. Buizer AI, de Sonneville LM, Veerman AJ. Effects of chemotherapy on neurocognitive function in 
children with acute lymphoblastic leukemia: a critical review of the literature. Pediatr Blood 
Cancer. 2009 Apr; 52(4):447–54. [PubMed: 19061221] 
Mendley et al. Page 10













32. Hooper SR, Gerson AC, Butler RW, et al. Neurocognitive functioning of children and adolescents 
with mild-to-moderate chronic kidney disease. Clin J Am Soc Nephrol. 2011; 6:1824–30. 
[PubMed: 21737850] 
33. McCabe DP, Roediger HL, McDaniel MA, et al. The relationship between working memory 
capacity and executive functioning: evidence for a common executive attention construct. 
Neuropsych. 2010; 24:222–43.
34. Wu K, Chan S, Leung P, et al. Components and Developmental Differences of Executive 
Functioning for School-Aged Children. Dev Neuropsych. 2011; 36:319–337.
35. Jefferson AL, Paul RH, Ozonoff A, et al. Evaluating elements of executive functioning as 
predictors of instrumental activities of daily living (IADLs). Arch Clin Neuropsychol. 2006; 21(4):
311–320. [PubMed: 16814980] 
36. Carlson SM, Moses LJ, Claxton LJ. Individual differences in executive functioning and theory of 
mind: An investigation of inhibitory control planning ability. J Exp Child Psychol. 2004; 87(4):
299–319. [PubMed: 15050456] 
37. Lyon, GR.; Krasnegor, NA., editors. Attention, memory, and executive function. Paul H. Brookes 
Publishing Company; Baltimore: 1996. 
38. Zelazo, PD.; Muller, U. The Wiley-Blackwell Handbook of Childhood Cognitive Development. 2. 
Vol. Chapter 22. Goswami U. Blackwell; Oxford, UK: 2010. Executive function in typical and 
atypical development. 
39. Pennington, B. Dimensions of executive functions in normal and abnormal development. In: 
Krasnegor, NA.; Lyon, GR.; Goldman-Rakic, PS.; Paul, H., editors. Development of Prefrontal 
Cortex. Brookes Publishing Company; Baltimore: 1997. p. 265-281.
40. Welsh MC, Pennington BF, Groisser DB. A normative developmental study of executive function: 
A window on the prefrontal function in children. Developmental Neuropsychology. 1991; 7:131–
149.
41. Korkman M, Kemp SL, Kirk U. Effects of age on neurocognitive measures of children ages 5 to 
12: A cross-sectional study on 800 children from the United States. Dev Neuropsychol. 2001; 
20(1):331–354. [PubMed: 11827092] 
42. Horton AM Jr, Soper HV, Reynolds CR. Executive functions in children with traumatic brain 
injury. Appl Neuropsychol. 2010; 17(2):99–103. [PubMed: 20467949] 
43. Gipson DS, Hooper SR, Duquette PJ, et al. Memory and executive functions in pediatric chronic 
kidney disease. Child Neuropsychol. 2006; 12:391–405. [PubMed: 16952886] 
44. Gerson AC, Wentz A, Abraham AG, Mendley SR, Hooper SR, Butler RW, Gipson DS, Lande 
MB, Shinnar S, Moxey-Mims MM, Warady BA, Furth SL. Health-related quality of life of 
children with mild to moderate chronic kidney disease. Pediatrics. 2010 Feb; 125(2):e349–57. 
[PubMed: 20083528] 
45. Lande MB, Gerson AC, Hooper SR, et al. Casual blood pressure and neurocognitive function in 
children with chronic kidney disease: a report of the children with chronic kidney disease cohort 
study. Clin J Am Soc Nephrol. 2011; 6:1831–7. [PubMed: 21700829] 
46. Fennell EB, Fennell RS, Mings E, et al. The effects of various modes of therapy for end stage renal 
disease on cognitive performance in a pediatric population--a preliminary report. Int J Pediatr 
Nephrol. 1986; 7:107–12. [PubMed: 3522456] 
47. Dennis M, Francis DJ, Cirino PT, Schachar R, Barnes MA, Fletcher JM. Why IQ is not a covariate 
in cognitive studies of neurodevelopmental disorders. J Int Neuropsychol Soc. 2009; 15:331–343. 
[PubMed: 19402919] 
48. Furth SL, Cole SR, Moxey-Mims M, et al. Design and methods of the Chronic Kidney Disease in 
Children (CKiD) prospective cohort study. Clin J Am Soc Nephrol. 2006; 1:1006–15. [PubMed: 
17699320] 
49. Schwartz GJ, Furth S, Cole SR, et al. Glomerular filtration rate via plasma iohexol disappearance: 
pilot study for chronic kidney disease in children. Kidney Int. 2006; 69:2070–7. [PubMed: 
16612328] 
50. Schwartz GJ, Munoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, Furth SL. New equations 
to estimate GFR in children with CKD. J Am Soc Nephrol. 2009; 20:629–37. [PubMed: 
19158356] 
Mendley et al. Page 11

























Mendley et al. Page 12
Table 1
Characteristics of study participants (N=340) at time of first executive function testing
Characteristic % (n) or Median [IQR]




 High school or less 41% (136)
 Some college 28% (91)
 College or more 31% (103)
Household Income
 <$36,000/year 38% (127)
 ≥$36,000/year 62% (204)
IQ < 85 22% (73)
Elevated Blood Pressurea 26% (78)
Premature Birth 12% (37)
Urine Protein:Creatinine ≥ 2 12% (38)
Duration of CKD, years 10 [6, 13]
eGFR, ml/min|1.73m2 43 [31, 53]
D-KEFS Total Achievement 10 [8, 11]
Digit Span Backward 9 [7, 11]
CPT-II Errors of Commission 54 [44, 60]
CPT-II Hit Reaction Time 47 [40, 54]
CPT-II Variability 49 [43, 59]
a
Defined as systolic or diastolic blood pressure ≥90th percentile for age, sex and height.
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